Adverse Event Profiles of Adalimumab in Children: A Disproportionality Analysis

Background: Adalimumab has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult rheumatoid arthritis (RA), and subsequently approved for pediatric treatment of various autoimmune diseases in children of different ages. Due to genetic differences between children an...

Full description

Bibliographic Details
Published in:Pharmaceuticals
Main Authors: Wenting Zhang, Ziqi Xu, Yamin Shu, Sainan Shu, Qilin Zhang
Format: Article
Language:English
Published: MDPI AG 2024-08-01
Subjects:
adalimumab
adverse event
children
disproportionality analysis
FAERS database
Online Access:https://www.mdpi.com/1424-8247/17/8/1028

Internet

https://www.mdpi.com/1424-8247/17/8/1028

Similar Items